Limits...
Chinese patent medicines for the treatment of the common cold: a systematic review of randomized clinical trials.

Chen W, Liu B, Wang LQ, Ren J, Liu JP - BMC Complement Altern Med (2014)

Bottom Line: A total of five RCTs were identified.All of the RCTs were of high risk of bias with flawed study design and poor methodological quality.All RCTs included children aged between 6 months to 14 years.

View Article: PubMed Central - PubMed

Affiliation: Centre For Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China. jianping_l@hotmail.com.

ABSTRACT

Background: Many Chinese patent medicines (CPMs) have been authorized by the Chinese State of Food and Drug Administration for the treatment of the common cold. A number of clinical trials have been conducted and published. However, there is no systematic review or meta-analysis on their efficacy and safety for the common cold to justify their clinical use.

Methods: We searched CENTRAL, MEDLINE, EMBASE, SinoMed, CNKI, VIP, China Important Conference Papers Database, China Dissertation Database, and online clinical trial registry websites for published and unpublished randomized clinical trials (RCTs) of CPMs for the common cold till 31 March 2013. Revman 5.2 software was used for data analysis with effect estimate presented as relative risk (RR) and mean difference (MD) with a 95% confidence interval (CI).

Results: A total of five RCTs were identified. All of the RCTs were of high risk of bias with flawed study design and poor methodological quality. All RCTs included children aged between 6 months to 14 years. Results of individual trials showed that Shuanghuanglian oral liquid (RR 4.00; 95% CI: 2.26 to 7.08), and Xiaoer Resuqing oral liquid (RR 1.43; 95% CI: 1.15 to 1.77) had higher cure rates compared with antivirus drugs. Most of the trials did not report adverse events, and the safety of CPMs was still uncertain.

Conclusions: Some CPMs showed a potential positive effect for the common cold on cure rate. However, due to the poor methodology quality and the defects in the clinical design of the included RCTs, such as the lack of placebo controlled trials, the inappropriate comparison intervention and outcome measurement, the confirmative conclusions on the beneficial effect of CPMs for the common cold could not be drawn.

Show MeSH

Related in: MedlinePlus

Forest plot of comparison of CPM with antivirus drugs on cure rate.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4129119&req=5

Fig3: Forest plot of comparison of CPM with antivirus drugs on cure rate.

Mentions: Three trials [9, 11, 13] compared CPMs with antivirus drugs on cure rate. Results showed that there was no difference between Chaihu injection and ribavirin injection (RR 0.78, 95% CI: 0.22 to 2.76), Shuanghuanglian oral liquid had higher cure rate compared with ribavirin injection (RR 4.00; 95% CI: 2.26 to 7.08), and Xiaoer Resuqing oral liquid had higher cure rate compared with moroxydine tablets (RR 1.43; 95% CI: 1.15 to 1.77) (FigureĀ 3).Figure 3


Chinese patent medicines for the treatment of the common cold: a systematic review of randomized clinical trials.

Chen W, Liu B, Wang LQ, Ren J, Liu JP - BMC Complement Altern Med (2014)

Forest plot of comparison of CPM with antivirus drugs on cure rate.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4129119&req=5

Fig3: Forest plot of comparison of CPM with antivirus drugs on cure rate.
Mentions: Three trials [9, 11, 13] compared CPMs with antivirus drugs on cure rate. Results showed that there was no difference between Chaihu injection and ribavirin injection (RR 0.78, 95% CI: 0.22 to 2.76), Shuanghuanglian oral liquid had higher cure rate compared with ribavirin injection (RR 4.00; 95% CI: 2.26 to 7.08), and Xiaoer Resuqing oral liquid had higher cure rate compared with moroxydine tablets (RR 1.43; 95% CI: 1.15 to 1.77) (FigureĀ 3).Figure 3

Bottom Line: A total of five RCTs were identified.All of the RCTs were of high risk of bias with flawed study design and poor methodological quality.All RCTs included children aged between 6 months to 14 years.

View Article: PubMed Central - PubMed

Affiliation: Centre For Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China. jianping_l@hotmail.com.

ABSTRACT

Background: Many Chinese patent medicines (CPMs) have been authorized by the Chinese State of Food and Drug Administration for the treatment of the common cold. A number of clinical trials have been conducted and published. However, there is no systematic review or meta-analysis on their efficacy and safety for the common cold to justify their clinical use.

Methods: We searched CENTRAL, MEDLINE, EMBASE, SinoMed, CNKI, VIP, China Important Conference Papers Database, China Dissertation Database, and online clinical trial registry websites for published and unpublished randomized clinical trials (RCTs) of CPMs for the common cold till 31 March 2013. Revman 5.2 software was used for data analysis with effect estimate presented as relative risk (RR) and mean difference (MD) with a 95% confidence interval (CI).

Results: A total of five RCTs were identified. All of the RCTs were of high risk of bias with flawed study design and poor methodological quality. All RCTs included children aged between 6 months to 14 years. Results of individual trials showed that Shuanghuanglian oral liquid (RR 4.00; 95% CI: 2.26 to 7.08), and Xiaoer Resuqing oral liquid (RR 1.43; 95% CI: 1.15 to 1.77) had higher cure rates compared with antivirus drugs. Most of the trials did not report adverse events, and the safety of CPMs was still uncertain.

Conclusions: Some CPMs showed a potential positive effect for the common cold on cure rate. However, due to the poor methodology quality and the defects in the clinical design of the included RCTs, such as the lack of placebo controlled trials, the inappropriate comparison intervention and outcome measurement, the confirmative conclusions on the beneficial effect of CPMs for the common cold could not be drawn.

Show MeSH
Related in: MedlinePlus